Clinical Trial Update: A Phase 2 Bridging Study to Assess the New Formulation of ETVAX [Phase 2]

View source ↗

Summary

A Phase 2 bridging study evaluating a new formulation of the ETVAX vaccine has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enterotoxigenic Escherichia Coli Infection
• Traveler Diarrhea

Drugs mentioned

• ETVAX (Enterotoxigenic Escherichia coli vaccine)

Snippet

Sponsor: Scandinavian Biopharma AB | Conditions: Healty Volunteers, Preventable Disease, Vaccine | Phase 2 | Status: COMPLETED | Results posted: 2025-08-19